Abstract
84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have